|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rearrangement of the mixed lineage leukemia (MLL; also known as lysine methyltransferase 2A) gene is a recurrent genomic aberration in acute myeloid leukemia (AML).
|
31789407 |
2020 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of MLL1 catalytic function is relevant to mixed-lineage leukemia, and targeting WDR5-MLL1 interaction could be a promising therapeutic strategy for leukemia harboring MLL1 fusion proteins.
|
30626558 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytogenetic analyses revealed additional genetic aberrations including trisomy 8 and t(9;11)(p21;q23) involving the mixed lineage leukemia ( MLL) gene.
|
30935343 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia.
|
31413090 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The WHO 2008 classification further delineated three categories: associated with t(9;22)/BCR-ABL1 fusion gene, associated with KMT2A (mixed lineage leukemia) rearrangements, and nonotherwise specified.
|
31033213 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite many attempts to understand mixed-lineage leukemia (MLL leukemia), effective therapies for this disease remain limited.
|
30651276 |
2019 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase 1 study, pinometostat was evaluated for safety and efficacy in adult patients with advanced acute leukemias, particularly those involving mixed lineage leukemia (<i>MLL</i>) gene rearrangements (<i>MLL-r</i>) resulting from 11q23 translocations.
|
29724899 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, DOT1L is believed to be involved in the development of MLL-rearranged leukemia driven by the MLL (mixed-lineage leukemia) fusion proteins, which thus to be a crucial target for leukemia therapy.
|
29534934 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features.
|
30143999 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Psip1</i> knockout mice were viable but showed several defects in hematopoiesis, reduced colony-forming activity in vitro, decreased expression of <i>Hox</i> genes in the hematopoietic stem cells, and decreased MLL occupancy at MLL target genes.
|
29084774 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that kinase-dependent phosphorylation of MLL1 represents a previously unknown oncogenic dependency that may be harnessed in the treatment of MLL-rearranged leukemia.
|
29997176 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated H3K4me3 methylases (mixed-lineage leukemia [MLL] complex) and H3K27me3 demethylases (JMJD3 and UTX) were dynamically expressed between early and late bell stage of human tooth germs and in cultured human dental papilla cells (hDPCs) during odontogenic induction.
|
28880717 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lineage switch following CAR-T therapy has been described in patients with KMT2A (mixed lineage leukemia) rearrangements, but not previously in any patient with ZNF384 fusion.
|
29797659 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacologically inhibiting this pathway substantially delays progression, and it improves survival of murine leukemia through stabilizing wild-type MLL protein, which displaces the MLL chimera from some of its target genes and, therefore, relieves the cellular oncogenic addiction to MLL chimeras.
|
28065413 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL5, assigned as KMT2E on the basis of its SET domain homology, was initially categorized under MLL (KMT2) family together with other six SET methyltransferase domain proteins (KMT2A-2D and 2F-2G).
|
28188343 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal rearrangements of the mixed lineage leukemia (MLL/KMT2A) gene leading to oncogenic MLL-fusion proteins occur in ~10% of acute leukemias and are associated with poor clinical outcomes, emphasizing the need for new treatment modalities.
|
27840424 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) lead to recruitment of DOT1L, to a multi-protein complex resulting in aberrant methylation of histone H3 lysine 79 at MLL target genes, and ultimately enhanced expression of critical genes for hematopoietic differentiation, including HOXA9 and MEIS1, and as such defines the established mechanism for leukemogenesis in MLL-rearrangement (MLL-r) leukemias.
|
28229434 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic rearrangements involving KMT2A gene are frequently involved in lymphoid, myeloid and mixed lineage leukemia.
|
28535805 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias.
|
28076791 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acute lymphoblastic leukemia (ALL) with mixed lineage leukemia (MLL) gene rearrangements (MLL+ALL) has a dismal prognosis and is characterized by high surface CD44 expression.
|
28569787 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acute myeloid leukemias (AMLs) with translocations of the mixed lineage leukemia (MLL/KMT2A) gene are common in young patients and are generally associated with poor clinical outcomes.
|
28911906 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite MLL proteins being postulated as essential for normal development, little is known about the specific functions of the different MLL lysine methyltransferases.
|
27992417 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fms-like tyrosine kinase 3 (FLT3) is highly expressed in mixed-lineage leukemia (MLL) gene-rearranged acute lymphoblastic leukemia (MLL+ALL) with a dismal prognosis.
|
28917156 |
2017 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Upon androgen stimulation, AR recruits the Protein kinase N1 (PKN1), which phosphorylates histone H3 at threonine 11, with subsequent recruitment of tryptophan, aspartic acid (WD) repeat-containing protein 5 (WDR5) and the su(var)3-9, enhancer of zeste, trithorax/mixed-lineage leukemia (SET1/MLL) histone methyltransferase complex to promote AR target gene activation and prostate cancer cell growth.
|
27268279 |
2016 |
|
MIXED LINEAGE LEUKEMIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MLL protein complex has been shown to interact with the androgen receptor via the MLL-menin subunit, thus promoting gene activation.
|
27705736 |
2016 |